Bristol Myers Squibb shares surge 10% as Q2 revenue of $12.2bn, up 9% YoY, driven by newer drugs' growth.
Bristol Myers Squibb's shares surged nearly 10% on Friday after the pharmaceutical company reported a stronger-than-expected Q2, with revenue of $12.2bn, up 9% YoY. The growth was driven by the company's newer drugs, such as Opdivo, Yervoy, and Opdualag, which boosted the Growth Portfolio's revenue to $5.6bn, up 18% YoY. The company also raised its full-year guidance, citing the continued demand for its cancer-fighting treatments.
July 26, 2024
8 Articles